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Abstract
Objective—Previous research has demonstrated an association between emotion recognition and 
apathy in a number of neurological conditions involving fronto-striatal pathology, including 
Parkinson’s disease and brain injury. In line with these findings, we aimed to determine whether 
apathetic participants with early Huntington’s disease (HD) were more impaired on an emotion 
recognition task compared to non-apathetic participants and healthy controls.
Method—We included 43 participants from the TRACK-HD study who reported apathy on the 
Problem Behaviours Assessment – short version (PBA-S), 67 participants who reported no apathy 
and 107 controls matched for age, sex and level of education. During their baseline TRACK-HD 
visit, participants completed a battery of cognitive and psychological tests including an emotion 
recognition task, the Hospital Depression and Anxiety Scale (HADS) and were assessed on the 
PBA-S.
Results—Compared to the non-apathetic group and the control group, the apathetic group were 
impaired on the recognition of happy facial expressions, after controlling for depression 
symptomology on the HADS and general disease progression (UHDRS total motor score). This 
was despite no difference between the apathetic and non-apathetic group on overall cognitive 
functioning assessed by a cognitive composite score.
Conclusions—Impairment of the recognition of happy expressions may be part of the clinical 
picture of apathy in HD. While shared reliance on fronto-striatal pathways may broadly explain 
associations between emotion recognition and apathy found across a number of patient groups, 
further work is needed to determine what relationships exist between recognition of specific 
emotions, distinct subtypes of apathy and underlying neuropathology.
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Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder caused by 
expanded CAG-repeat in the Huntingtin gene. The disease is characterised by the gradual 
emergence and progression of motor impairment, neurocognitive deficits and psychiatric 
symptoms. Subtle neurocognitive deficits can precede the emergence of the motor symptoms 
of HD (Stout et al., 2011; Paulsen, Miller, Hayes, & Shaw, 2017) and commonly include 
impairments in social cognition, such as facial emotion recognition (Bora, Velakoulis, & 
Walterfang, 2016; Henley et al., 2012). Recognition of negative emotions appears to be 
predominantly affected (Tabrizi et al., 2009). An important unanswered question, though, is 
whether these social cognition deficits are a component of broader neuropsychiatric 
syndromes which affect social functioning more generally (Kordsachia, Labuschagne, & 
Stout, 2017).
Apathy is a prevalent neuropsychiatric symptom in patients with HD (Camacho, Barker, & 
Mason, 2018) and has important implications for the patients’ functional capacity of the 
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patient (Hamilton et al., 2003; van Duijn et al., 2014), quality of life (Eddy & Rickards, 
2013), employment (Jacobs, Hart & Roos, 2018), and social functioning (Fritz et al., 2018). 
Indeed, both patients and caregivers rate apathy in the top three most impactful features of 
the disease (Simpson, Lovecky, Kogan, Vetter, & Yohrling, 2016). Thus, furthering our 
understanding of apathy in HD has the potential to improve the quality of life of both 
patients and caregivers. Clinical apathy is defined as a lack of motivation that has an impact 
on activities of daily living, leading to a lack of spontaneous and sustained goal-oriented 
activities (Levy & Dubois, 2006). As well as being common in HD, apathy is also 
commonly reported following lesions of the prefrontal cortex (PFC) (Eslinger & Damasio, 
1985; Stuss, Van Reekum, & Murphy, 2000) or basal ganglia (Bhatia & Marsden, 1994; 
Engelborghs, Marien, Pickut, Verstraeten, & De Deyn, 2000; Ghika-Schmid & 
Bogousslavsky, 2000), as well in Parkinson’s disease (PD; Aarsland et al., 1999; Aarsland, 
Litvan, & Larsen, 2001; Isella et al., 2002; Pluck & Brown, 2002) and progressive 
supranuclear palsy (Aarsland et al., 2001; Litvan, Paulsen, Mega, & Cummings, 1998). 
Thus, apathy can be considered a clinical consequence of disruption to the of the PFC-basal 
ganglia axis, a functional system critically involved in the generation and control of 
purposeful behaviour. The orbito-medial PFC also appears to be critical for processing 
affective information in the faces of others (Adolphs, Tranel, & Damasio, 2003). In HD 
specifically, both emotion recognition deficits and apathy have been associated with atrophy 
and white matter changes of the orbitofrontal cortex and striatum (Delmaire et al., 2013; 
Henley et al., 2008; Ille et al., 2011; Scahill et al., 2009). Thus, an association between 
emotion recognition and apathy may be predicted on the grounds of shared neuropathology.
In addition to sharing overlapping anatomical underpinnings, emotion recognition and 
apathy may be mechanistically linked as well. One proposed mechanism of apathy is the 
inability to associate the affective value of rewards with ongoing and forthcoming behaviour 
(Levy & Dubois, 2006). Since affect is important in providing the motivational value of an 
action, a loss of the link between affect and behaviours leads to a loss of incentive to 
perform those behaviours. Specifically, connectivity of the limbic structures to the orbital 
and medial PFC is the route through which this affective information is thought to influence 
behaviour (Rolls, 2000). This affective information may be particularly important in 
motivating behaviour in the social domain, where the behavioural outcomes we experience 
have strong emotional value. In support of this, problems with social and emotional goal-
directed behaviour form a significant part of the clinical picture of apathy, manifesting as 
disinterest in social interactions and resulting in social withdrawal (Levy & Dubois, 2006). 
This loss of motivation for social experiences may result from a lack of affective 
engagement with the social rewards which usually motivate such behaviour (Ruff & Fehr, 
2014). A lack of engagement with social stimuli, such as the facial expressions of others, 
may also preclude the processing of information contained within the stimuli and result in 
impairments in emotion recognition.
Indeed, an association between apathy and emotion recognition has been demonstrated in a 
range of neurologic conditions with fronto-striatal pathology, including PD (Drapier et al., 
2006; Martínez-Corral et al., 2010; Robert et al., 2014; Schroeder, 2004), brain injury 
(Njomboro & Deb, 2014; Njomboro, Humphreys, & Deb, 2014), thalamic infarction with 
damage to the striatal-ventral pallidal-thalamic-frontomesial limbic loop (Ioannidis et al., 
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2013) and aneurysmal subarachnoid haemorrhage (Buunk et al., 2017). In one study, 
conjunction analyses showed that overlap between the networks underlying apathy and 
emotion recognition impairments included the right premotor cortex, right orbitofrontal 
cortex, left middle frontal gyrus and left posterior cingulate gyrus in participants with PD 
(Robert et al., 2014). Thus, there is evidence from a range of patient groups to suggest that 
emotion recognition deficits frequently co-occur with apathy as the result of damage to 
shared brain circuitry. These results together support the existence of an anatomical and 
functional relationship between apathy and impaired emotion recognition in neurological 
patients, involved in both motivation and emotion processes.
The relationship between apathy and emotion perception has only once been assessed in an 
HD sample. The study found that performance on the Emotion Evaluation Test of The 
Awareness of Social Inference Test (TASIT-EET) was associated with informant ratings of 
apathy on the Frontal System Behavior Scale (FrsBe) above general disease progression 
(Kempnich et al., 2017). The current study aimed to replicate these results in a larger, 
multinational sample of participants with HD. In line with past research in HD and other 
neurological samples, we hypothesised that apathetic participants with early HD from the 
TRACK-HD study would be impaired on an emotion recognition task compared to non-
apathetic participants and healthy controls matched for age and level of education. We also 
controlled for disease progression and symptoms of depression, which both may contribute 




Participants were those with early HD and controls who completed the baseline visit of the 
TRACK-HD study. Premanifest participants were not included in the current analysis as 
only a small number of them met criteria for apathy. The Track-HD study included 123 
control subjects and 123 early-stage HD participants from four different sites (National 
Hospital for Neurology and Neurosurgery, London, UK, the Department of Medical 
Genetics at the University of British Columbia, Vancouver, Canada, the Department of 
Genetics and Cytogenetics at the Hôpital de la Salpêtrière-Université Pierre and Marie 
Curie, Paris, France, and the Department of Neurology at Leiden University Medical Centre, 
Leiden, Netherland). Participants met the following inclusion criteria: aged between 18 and 
65 years; ability to tolerate MRI and biosample collection; absence of major psychiatric 
disorder or history of significant head injury at time of enrolment. Subjects were not 
excluded based on medication usage, unless actively part of an experimental therapeutic 
trial. Early HD participants were defined as having a diagnostic confidence score of 4 on the 
UHDRS motor assessment. Early HD subjects required presence of motor features 
consistent with HD, and a diagnostic confidence score of 4, according to the well-
established Unified Huntington's Disease Rating Scale (UHDRS) (Huntington Study group 
1996). Early HD subjects were required to be within Shoulson and Fahn stage I or II 
assessed according to UHDRS total functional capacity (TFC ≥ 7) (Shoulson & Fahn, 1979).
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Of the 123 controls, 8 were excluded because they had a PBA apathy score of >1 indicating 
apathy of at least mild severity. A further 2 were excluded because they did not complete the 
HADS and a further 6 were excluded because they did not complete the emotion recognition 
task. The remaining 107 controls were included in the current analysis. Of the 123 
participants with HD who completed the baseline visit, 110 were included in the analysis. 
Nine were excluded because they did not complete the emotion recognition task and a 
further 4 were excluded because they did not complete the HADS. T-tests determined that 
the groups did not differ in terms of age and Chi-squared tests determined that the groups 
did not differ in proportions of males and females, or proportions of participants at different 
levels of education (see Table 1). Demographic characteristics of the groups can be seen in 
Table 1.
Materials
Problem Behaviour Assessment—The Problem Behaviour Assessment – Short 
version (PBA-S; Callaghan et al., 2015) is a semi-structured interview which assesses 10 
neuropsychiatric symptoms common in HD: depressed mood, suicidal ideation, anxiety, 
irritability, angry outbursts / aggressive behaviour, lack of motivation (apathy, social and 
household activities, enthusiasm/spontaneity), perseveration, paranoid thinking / delusions, 
hallucinations and behaviour suggesting disorientation. The PBA-S is a shortened version of 
the earlier Problem Behaviours Assessment for HD (Craufurd et al., 2001). Study staff who 
had been trained to criterion for standardised PBA-S interview guidelines administered the 
measure to all TRACK-HD participants. Each neuropsychiatric symptom is rated in terms of 
its severity and its frequency in the last month. The interviewers are provided with the 
following suggested prompts for assessing apathy in patients: “In the past four weeks, have 
you found that you have lost interest in things that used to be important to you?”, “Are you 
just as interested as always in trying new things or starting new projects?”, “Do you have to 
be pushed to get started on chores that need doing?”, “Do you leave it to friends for taking 
the initiative for organising social activities?”, “Do you sit around and do a lot of nothing?”. 
The interviewer may also follow-up with any additional questions which help them to 
accurately rate the behaviour. Based on responses provided by the participants themselves or 
by a companion present at the interview (usually a partner or family member), the 
interviewer rates both the severity of the apathy in the last month and the frequency with 
which it has occurred. Severity was rated on a scale from 0 to 4 (0=absent, 1=slight, 
questionable, 2=mild, 3=moderate, 4=severe) and frequency was rated on a scale of 0 to 4 
(0=never/almost never; 1=seldom, less than once/week; 2=sometimes, up to 4 times per 
week; 3=frequently, most days of the week; 4=daily/almost daily for most or all of the day). 
The score of interest for this study was the total apathy score, which is the product of the 
severity and frequency score for the apathy item. The cut-off for the apathetic group was a 
score of >1, indicating that apathy was of at least mild severity.
Hospital Anxiety/Depression Scale (HADS)—The HADS (Zigmond & Snaith, 1983) 
is a commercially available scale with 14 items, 7 measuring anxiety and 7 measuring 
depression. Each item is rated on a four-point scale. The depression score was used for this 
analysis.
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Emotion Recognition Task—Facial stimuli from the Ekman and Friesen face stimulus 
set (Ekman & Friesen, 1976) were presented on a Lenovo ThinkPad X61 tablet PC (IBM, 
New York) that had a 12 inch LCD stylus-sensitive screen with 1400×1050 pixel resolution. 
For each task trial, a face expressing one of six basic emotions (anger, disgust, fear, 
happiness, sadness and surprise) or a neutral expression was displayed in the middle of the 
screen, with seven emotion labels displayed at the bottom of the screen. The face stimuli 
were 60 mm×90 mm and were presented in a random order for each participant. Each of the 
emotion labels were presented in a 26 mm×13 mm ellipse. Across participants, the array of 
response labels was randomly displayed but within each participant it was kept consistent 
across trials. Seven practice trials (one for each emotion and the neutral face) preceded the 
experimental trials to familiarise participants with the response labels. There were 70 
experimental trials, 10 for each of the six emotional and neutral stimulus types. The faces 
were displayed for 4000 ms and the emotion response labels were displayed for up to 8000 
ms, allowing participants time to respond after the face had disappeared. All trials were 
followed by a 1000 ms inter-trial interval. Participants were instructed to sit approximately 
30 cm from the screen and were asked to respond by tapping the appropriate label with a 
stylus held in their dominant hand.
General Cognitive Tasks—For an overall measure of cognitive ability, a cognitive 
composite score was created using scores from the five main cognitive measures completed 
on visit 1 of the TRACK-HD study, detailed below (Trails A, Trails B, symbol digit 
modalities task, stroop word reading task, spot the change). First, z-scores were calculated 
for each test using the mean and standard deviation of the whole sample. These z-scores 
were then summed to create the composite. All cognitive tasks were inter-correlated with r 
values between .44 and .84 (all p’s <.001). A principle components analysis yielded a single 
component with an Eigenvector >1. For the component with the eigenvalue >1, all variables 
yielded similar values (ranging from .75 to .91), making it reasonable to define the global 
composite as a sum of the standardised scores.
Trails A and B. The Trail Making Test (TMT; Reitan, 1955) is a test of processing speed, 
sequencing, mental flexibility and visual-motor skills. In part A, the subject uses a pencil to 
connect a series of 25 encircled numbers in numerical order. In part B, the subject connects 
25 encircled numbers and letters in numerical and alphabetical order, alternating between 
the numbers and letters. For example, the first number “1” is followed by the first letter “A,” 
followed by the second number “2” then second letter “B” and so on. The numbers and 
letters are placed in a semi-random fixed order, in such a manner as to avoid overlapping 
lines being drawn by the examinee. The variable of interest was time to completion for parts 
A and B.
Symbol Digit Modalities Test (SDMT). The SDMT is a test of visuomotor integration, 
involving visual scanning, tracking, and motor speed (Smith, 1982). In the task, participants 
are provided with a key at the top of the page which matches the numbers 1 to 9 with a 
series of 9 different symbols. The test consists of blank boxes underneath a series of symbols 
into which participants must write the corresponding number as quickly as possible. The 
variable of interest was the total number of boxes filled correctly in 90 seconds.
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Stroop Word Test. The Stroop Test has three conditions that require visual scanning, 
cognitive control and processing speed (Golden & Freshwater, 1978). Because the Word 
Reading condition (the first condition normally presented) is the most sensitive in 
premanifest HD, it was the only Stroop condition used in the Track cognitive battery (Stout 
et al., 2008). Subjects were given a card on which the names of colours were printed in black 
ink and must read as many words as they are able in 45 seconds. The variable of interest was 
the number of words correct after 45 seconds.
Spot the change. Spot the Change is a computerised test of visuospatial working memory, 
which was developed based on earlier work by Cowan and colleagues (2005). On each trial 
of this test, participants viewed a display of five randomly placed coloured squares for 250 
msec (target display). After a 1000 msec delay, the target display was replaced with a 
display of five squares in the same locations, but one of the squares was circled. The non-
circled squares remained the same colour as they appeared previously. However, on half of 
the trials, the circled square changed colour. The participant was asked to indicate whether 
the circled square was the same colour or a different colour, as quickly and accurately as 
possible. There were 32 trials. The variable of interest was Cowan’s k22, the number of 
correct trials, adjusted for guessing as follows:
k = 5 * number correct hits/32 + number correct rejections/32 − 1 .
Procedure
At each visit participants completed a battery of cognitive tests, multiple neuropsychiatric 
questionnaires, gave blood samples and had an MRI scan. In about 90% of participants, all 
of this data was collected in one visit. Written informed consent was obtained from all 
subjects according to the Declaration of Helsinki and the study was approved by local ethics 
committees.
Statistical Analysis
The 110 participants with HD were split into two groups: those with a PBA apathy score of 
>1 (HD-Apathy; n=43) and those with a PBA apathy score of ≤1 (HD-No Apathy; n=67). 
Significant apathy was defined as a PBA apathy score of >1, indicating apathy that is of at 
least mild severity.
First, cognitive composite scores were compared across groups using a univariate analysis of 
covariance (ANCOVA) with HADS depression score entered as a covariate. Additionally, to 
compare the HD-Apathy group with the HD-No Apathy group while controlling for the 
effect of disease burden, the analysis was repeated with the addition of the UHDRS total 
motor score (TMS) as a covariate.
Next, recognition scores for each emotion were compared between groups using a mixed 
ANCOVA, with the HADS depression score entered as a covariate, group (HA-Apathy, HD-
No Apathy, and controls) as the between-subjects factor, and emotion (happiness, surprise, 
neutral, fear, disgust, anger, and sadness) as the within-subjects factor. Additionally, to 
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compare the HD-Apathy group with the HD-No Apathy while controlling for the effect of 
disease progression, the analysis was repeated with the addition of TMS as a covariate.
Results
The HD-Apathy and HD-No Apathy groups did not differ in CAG repeat length. However, 
the HD-Apathy group had higher disease burden (DBS), higher total motor score (TMS), 
and lower functional capacity (TFC). The disease burden score (DBS) score is calculated 
from the formula (age x [CAG-35.5]), and represents an estimate of an individual’s lifetime 
exposure to mutant huntingtin, at any age, before or after motor onset (Penney, Vonsattel, 
MacDonald, Gusella & Myers, 1997). The HD groups were more likely than the control 
group, and the HD-Apathy group were more likely than the HD-No Apathy group, to take 
both neuroleptic medications and SSRIs (see Table 1).
Overall Cognitive Ability
Of all the participants, 3 controls, 7 apathetic participants and 3 non-apathetic participants 
did not have a composite score as they were unable to complete all of the cognitive 
measures. The ANCOVA with HADS depression and study site entered as covariates 
revealed a significant main effect of group, F(4,203)=99.08, p<.001, partial η2=.49. Post-hoc 
pairwise comparisons revealed that the control group had significantly greater cognitive 
composite scores (M=4.11, SD=3.04) than both the HD-Apathy (M=-5.44, SD=4.68) and 
HD-No Apathy (M=-2.74, SD=3.74) groups, p<.001. After additionally controlling for 
TMS, there was no significant difference between cognitive composite scores for the HD-
Apathy and HD-No Apathy groups, p=.111.
Emotion Recognition
The ANCOVA with HADS depression and study site entered as covariates revealed a 
significant effect of group, F(2,212)=84.38, p<.001, partial η2=.44, a significant effect of 
emotion, F(6,1272)=27.58, p<.001, partial η2=.12, and an emotion by group interaction, 
F(12,1272)=2.67, p=.001, partial η2=.03. Bonferroni post-hoc pairwise comparisons showed 
that the control group (M=54.01, SD=5.69) had higher emotion recognition scores than HD-
No Apathy group (M=41.93, SD=8.96, p<.001), who had higher scores than the HD-Apathy 
group (M=35.88, SD=10.34, p=.005). In order to examine the interaction effect, univariate 
ANOVAs comparing scores for the three groups were conducted separately for each 
emotion, with HADS depression and study site entered as covariates. The Bonferroni 
corrected threshold was α = .007 (=.05/7). These analyses revealed that while the control 
group performed better than the HD-No Apathy group on every emotion (p<.001 in each 
case), the HD-Apathy group differed from the HD-No Apathy group for recognition of 
happiness (<.001), but not for recognition of surprise (p=.064), fear (p=.074), neutral (p=.
195), sadness (p=.312), anger (p=.658) or disgust (p=.197).
Next, these analyses were repeated with the addition of TMS as a covariate (as well as 
HADS depression and study site), to control for the effect of disease progression, which 
differed between the HD-Apathy and HD-No Apathy group. The results remained the same, 
whereby the HD-Apathy group differed from the HD-No Apathy group for recognition of 
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happiness (p=.002), but not for recognition of surprise (p=.353), fear (p=.141), neutral (p=.
718), sadness (p=.535), anger (p=.765) or disgust (p=.517). The effect size for the difference 
between apathetic and non-apathetic participants on recognition of happy expressions was 
d=.66, an effect of medium size. Entering neuroleptic use, SSRI use and the cognitive 
composite as covariates did not change the results (p=.016 for difference between HD-
Apathy and HD-No Apathy on recognition of happy expressions). Results of group 
comparisons for each emotion can be found in Table 2.
Discussion
In line with past research on emotion recognition in patients with early Huntington’s disease 
(for a recent meta-analysis see Bora et al., 2016), we found that participants with HD who 
did not have apathy were impaired on recognition of all basic emotions compared to 
controls. Additionally, in partial agreement with our hypothesis, we found a specific 
impairment in the recognition of happy facial expressions in apathetic participants with HD 
compared to non-apathetic participants, after controlling for disease progression and 
symptoms of depression. Further, this impairment was found despite no difference in general 
cognitive functioning between the two groups. One previous study found that overall 
emotion recognition score on the TASIT was related to FrsBe apathy scores in a smaller 
sample of participants with HD (Kempnich et al., 2017). Kempnich and colleagues, however, 
did not explore relationships with specific emotions and thus may have overlooked the 
possibility of particular emotions driving the effect. Although causal conclusions cannot be 
made based on the current analysis, these results suggest that impairments in the recognition 
of happy expressions may be a part of the clinical picture of apathy in HD.
One hypothesis about the link between emotion recognition and apathy is that damage to 
orbitomedial fronto-striatal pathways results in deficits in social reward processing, 
contributing to both problems with emotion recognition and reduced motivation for social 
behaviour. The orbitofrontal cortex is critical for processing rewards which motivate 
behaviour (Rolls, 2000) and for processing the affective information in faces (Adolphs, 
2002). In HD specifically, both apathy and emotion recognition is related to atrophy or white 
matter changes in the orbito-medial PFC and striatum (Delmaire et al., 2013; Henley et al., 
2008; Ille et al., 2011; Scahill et al., 2009). Thus, the neuropathology underpinning apathy 
and emotion recognition impairments in HD overlap. However, it is predominantly the 
recognition of negative emotions which has been linked to this pathology in HD. It is not 
clear, then, from this account, why the recognition of happiness alone would be associated 
with apathy.
Indeed, that apathetic HD participants differ from non-apathetic HD participants only on 
recognition of happy expressions is a point of convergence from findings in other 
neurological patient groups. Impairments across numerous, typically negative, emotions 
have been found in apathetic participants with PD, AD and brain injury (Buunk et al., 2017; 
Martínez-Corral et al., 2010; Njomboro et al., 2014; Robert et al., 2014). Further, in PD, 
non-apathetic participants were just as good as controls on emotion recognition, leading the 
authors to conclude that apathy accounted for the entire disease effect on emotion 
recognition. This is in contrast to our finding that the specific impairment in the apathetic 
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group on happy expressions was in addition to a general disease-related impairment across 
all emotions. However, with studies using different measures of apathy and different 
measures of emotion recognition, it is difficult to compare results. Additionally, most 
research, including the current study, has not delineated cognitive, behavioural and affective 
apathy, which may have distinct relationships with emotion recognition. Cognitive apathy, 
for instance, is likely to affect recognition particularly of more difficult emotions. Affective 
apathy, on the other hand, could have stronger relationships with recognition of more 
‘social’ emotions. Further, these apathy subtypes are associated with different underlying 
neuropathology (Levy & Dubois, 2006). Cognitive apathy, for instance, is associated with 
the dorsolateral prefrontal cortex and its connections with limbic areas while affective 
apathy is associated with the orbito-medial prefrontal cortex and its connections with limbic 
areas (Moretti & Signori, 2016). Thus, the relationships between recognition of different 
emotions, different apathy presentations, and their underlying neuropathology in people with 
HD need to be explored in future research.
The specificity of the impairment in recognition of happy expressions among apathetic 
participants in this study raises some interesting questions. In our emotion recognition task, 
happiness was the only positive emotion tested, and thus the only emotion tested that 
represents a rewarding stimulus associated with social approach motivation. This raises the 
question of whether other positive social emotions would be affected to a greater degree in 
apathetic compared to non-apathetic participants with HD. Typically, only Ekman’s six 
‘basic’ emotions are tested on emotion recognition tests, which are primarily negative 
emotions. These basic emotions include those that are experienced rarely in everyday life 
and are arguably not particularly social in nature, such as fear. In contrast, there are a wealth 
of positive social emotions that we experience on the faces of others on a daily basis, 
including interest, amusement, and excitement, which are important in motivating social 
behaviour. Future research should seek to determine whether recognition of these other 
positive social emotions are impaired in apathetic participants compared to non-apathetic 
participants.
The specificity of the relationship between recognition of happy expressions and apathy is 
also of interest because happiness is the easiest of the six basic emotions to recognise and 
reliably produces near ceiling effects in healthy controls (Rosenberg, McDonald, Dethier, 
Kessels, & Westbrook, 2014). Perhaps due to happiness being relatively easy to identify, 
recognition of happy expressions is only affected in later stages of HD and with much 
smaller effect sizes than for impairments in recognition of other emotions (Bora et al., 
2016). As such, a more sensitive measure of recognition of happy expressions may reveal a 
larger effect of apathy. The most common way to increase the difficulty of expression 
recognition tasks is to include stimuli in which the emotion is not expressed at full intensity. 
The use of such tasks and the inclusion of more positive emotions in future research will 
help to clarify the relationship between expression recognition and apathy.
An important limitation of the current study was that the PBA measure of apathy was unable 
to distinguish between different types of apathy, namely, cognitive, affective and behavioural 
apathy. Indeed, there is some evidence that emotion recognition may be specifically 
associated with affective apathy in people with brain injury (Njomboro & Deb, 2014), but 
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this needs to be further explored in HD. Further, in this study apathy was measured by a 
single item on the PBA-S, and thus may not always be sensitive to detecting apathy. Another 
limitation is that although the apathetic and non-apathetic groups did not differ on the 
cognitive composite score, a greater proportion of apathetic patients (9%) compared to non-
apathetic (4%) participants and controls (2%) were unable to complete all cognitive tasks. 
This indicates that there may have be some cognitive impairment in the apathetic group that 
was not tapped by the cognitive composite score. On the other hand, refusal to complete 
tasks may have also contributed to the missing data in the apathetic group. Further, the 
apathetic group did have a higher disease burden score, higher total motor score and lower 
functional capacity, indicating that they were slightly more advanced in disease stage than 
the non-apathetic group. To address this, we controlled for disease severity in the analyses 
by adjusting for total motor score. Moreover, the relationship with happiness but not the 
other emotion domains suggests this is not just an overall disease stage effect but instead 
may represent a more specific association between apathy and impaired recognition of 
happiness.
The current study demonstrated a specific impairment in the recognition of happy 
expressions in apathetic compared with non-apathetic participants. This is partially in line 
with the broader emotion recognition impairments found previously in apathetic participants 
with HD and other neurological disorders (Buunk et al., 2017; Kempnich et al., 2017; 
Martínez-Corral et al., 2010; Njomboro et al., 2014; Robert et al., 2014). While shared 
reliance on fronto-striatal pathways may broadly explain associations between emotion 
recognition and apathy found across a number of patient groups, further work is needed to 
determine what relationships exist between recognition of specific emotions, distinct 
subtypes of apathy and underlying neuropathology.
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